Regeneron Pharmacueticals and Teva Pharmaceutical Report Positive Topline Phase 3 Clinical Trial Results of Fasinumab
On August 16, Regeneron Pharmaceuticals, Inc. (REGN) and Teva Pharmaceutical Industries Ltd. (TEVA) announced positive topline results from a Phase 3 clinical trial of Fasinumbab in patients with chronic pain from osteoarthritis of the knee or hip. After 16 weeks, the study met both co-primary endpoints as well as all key secondary endpoints. Patients treated with Fasinumab experienced significantly less pain and improved functional ability.
Sonal detected the event and sent an alert at 7:00 am. The next trade took place at 7:01 am for $22.54. Teva opened for regular market trading at $22.62. The stock price gained 7% during the event day to close at $24.11.
If you want to learn more about trading on clinical trial results, visit the Knowledge Center.
To see the latest weekly webinar, you can visit our Live Webinar page.
Subscribe here if you would like to start receiving these signals in real-time and start trading!